Reported Saturday, Vera Therapeutics Presented 72-week eGFR Stabilization And Rapid Hematuria Improvement In Phase 2b ORIGIN Study Of Atacicept In IgAN At The 61st European Renal Association Congress
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics presented positive 72-week data from its Phase 2b ORIGIN study of Atacicept in IgAN at the 61st European Renal Association Congress, showing eGFR stabilization and rapid hematuria improvement.
May 28, 2024 | 7:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics presented positive 72-week data from its Phase 2b ORIGIN study of Atacicept in IgAN, showing eGFR stabilization and rapid hematuria improvement, which could boost investor confidence.
The positive data from the Phase 2b study indicates potential efficacy of Atacicept in treating IgAN, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100